133 related articles for article (PubMed ID: 36658307)
1. Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients.
Chauhan PS; Shiang A; Alahi I; Sundby RT; Feng W; Gungoren B; Nawaf C; Chen K; Babbra RK; Harris PK; Qaium F; Hatscher C; Antiporda A; Brunt L; Mayer LR; Shern JF; Baumann BC; Kim EH; Reimers MA; Smith ZL; Chaudhuri AA
NPJ Precis Oncol; 2023 Jan; 7(1):6. PubMed ID: 36658307
[TBL] [Abstract][Full Text] [Related]
2. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA
PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379
[TBL] [Abstract][Full Text] [Related]
3. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.
Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420
[TBL] [Abstract][Full Text] [Related]
4. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
Nordentoft I; Lindskrog SV; Birkenkamp-Demtröder K; Gonzalez S; Kuzman M; Levatic J; Glavas D; Ptashkin R; Smadbeck J; Afterman D; Lauterman T; Cohen Y; Donenhirsh Z; Tavassoly I; Alon U; Frydendahl A; Rasmussen MH; Andersen CL; Lamy P; Knudsen M; Polak P; Zviran A; Oklander B; Agerbæk M; Jensen JB; Dyrskjøt L
Eur Urol; 2024 May; ():. PubMed ID: 38811314
[TBL] [Abstract][Full Text] [Related]
5. Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.
Szymanski JJ; Sundby RT; Jones PA; Srihari D; Earland N; Harris PK; Feng W; Qaium F; Lei H; Roberts D; Landeau M; Bell J; Huang Y; Hoffman L; Spencer M; Spraker MB; Ding L; Widemann BC; Shern JF; Hirbe AC; Chaudhuri AA
PLoS Med; 2021 Aug; 18(8):e1003734. PubMed ID: 34464388
[TBL] [Abstract][Full Text] [Related]
6. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature.
Green EA; Li R; Albiges L; Choueiri TK; Freedman M; Pal S; Dyrskjøt L; Kamat AM
Eur Urol Oncol; 2021 Dec; 4(6):893-903. PubMed ID: 33975782
[TBL] [Abstract][Full Text] [Related]
7. Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet?
Thakral D; Das N; Basnal A; Gupta R
Am J Blood Res; 2020; 10(3):26-45. PubMed ID: 32685257
[TBL] [Abstract][Full Text] [Related]
8. Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study.
Lee JS; Han Y; Yun WG; Kwon W; Kim H; Jeong H; Seo MS; Park Y; Cho SI; Kim H; Kim JY; Seong MW; Jang JY; Park SS
Clin Chem; 2022 Dec; 68(12):1509-1518. PubMed ID: 36177751
[TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.
Pagès M; Rotem D; Gydush G; Reed S; Rhoades J; Ha G; Lo C; Fleharty M; Duran M; Jones R; Becker S; Haller M; Sinai CE; Goumnerova L; Golub TR; Love JC; Ligon KL; Wright KD; Adalsteinsson VA; Beroukhim R; Bandopadhayay P
Neuro Oncol; 2022 Aug; 24(8):1352-1363. PubMed ID: 34984433
[TBL] [Abstract][Full Text] [Related]
10. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
[No Abstract] [Full Text] [Related]
11. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction.
Li X; Liu T; Bacchiocchi A; Li M; Cheng W; Wittkop T; Mendez F; Wang Y; Tang P; Yao Q; Bosenberg MW; Sznol M; Yan Q; Faham M; Weng L; Halaban R; Jin H; Hu Z
medRxiv; 2024 Jan; ():. PubMed ID: 38260271
[TBL] [Abstract][Full Text] [Related]
12. Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA.
Liu W; Li Y; Tang Y; Song Q; Wang J; Li N; Chen S; Shi J; Wang S; Li Y; Jiao Y; Zeng Y; Jin J
EBioMedicine; 2022 Apr; 78():103945. PubMed ID: 35306340
[TBL] [Abstract][Full Text] [Related]
13. PEAC: An Ultrasensitive and Cost-Effective MRD Detection System in Non-small Cell Lung Cancer Using Plasma Specimen.
Xu J; Pu Y; Lin R; Xiao S; Fu Y; Wang T
Front Med (Lausanne); 2022; 9():822200. PubMed ID: 35308511
[TBL] [Abstract][Full Text] [Related]
14. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
[TBL] [Abstract][Full Text] [Related]
15. Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content.
Ganesamoorthy D; Robertson AJ; Chen W; Hall MB; Cao MD; Ferguson K; Lakhani SR; Nones K; Simpson PT; Coin LJM
BMC Cancer; 2022 Jan; 22(1):85. PubMed ID: 35057759
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.
Yue D; Liu W; Chen C; Zhang T; Ma Y; Cui L; Gu Y; Bei T; Zhao X; Zhang B; Bai Y; Romero A; Xu-Welliver M; Wang C; Zhang Z; Zhang B
Transl Lung Cancer Res; 2022 Feb; 11(2):263-276. PubMed ID: 35280315
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer.
Jiang J; Ye S; Xu Y; Chang L; Hu X; Ru G; Guo Y; Yi X; Yang L; Huang D
Front Oncol; 2020; 10():1220. PubMed ID: 32850360
[TBL] [Abstract][Full Text] [Related]
18. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer.
Azad TD; Chaudhuri AA; Fang P; Qiao Y; Esfahani MS; Chabon JJ; Hamilton EG; Yang YD; Lovejoy A; Newman AM; Kurtz DM; Jin M; Schroers-Martin J; Stehr H; Liu CL; Hui AB; Patel V; Maru D; Lin SH; Alizadeh AA; Diehn M
Gastroenterology; 2020 Feb; 158(3):494-505.e6. PubMed ID: 31711920
[TBL] [Abstract][Full Text] [Related]
20. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA.
Henriksen TV; Reinert T; Christensen E; Sethi H; Birkenkamp-Demtröder K; Gögenur M; Gögenur I; Zimmermann BG; ; Dyrskjøt L; Andersen CL
Mol Oncol; 2020 Aug; 14(8):1670-1679. PubMed ID: 32471011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
